A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia (Protocol A0081224)
Phase of Trial: Phase III
Latest Information Update: 01 Jul 2017
At a glance
- Drugs Pregabalin (Primary)
- Indications Postherpetic neuralgia
- Focus Registrational; Therapeutic Use
- Sponsors Pfizer
- 14 Oct 2014 Status changed from recruiting to completed according to ClinicalTrials.gov record.
- 01 Oct 2014 Status changed from suspended to recruiting as reported by ClinicalTrials.gov.
- 25 Feb 2014 Planned End Date changed from 1 Mar 2014 to 1 Sep 2014 according to ClinicalTrials.gov record.